Author: Toropov, Andrey A.; Toropova, Alla P.; Veselinović, Aleksandar M.; Leszczynska, Danuta; Leszczynski, Jerzy
Title: SARS-CoV M(pro) inhibitory activity of aromatic disulfide compounds: QSAR model Cord-id: 101mkj28 Document date: 2020_9_9
ID: 101mkj28
Snippet: The main protease (M(pro)) of SARS-associated coronavirus (SARS-CoV) had caused a high rate of mortality in 2003. Current events (2019–2020) substantiate important challenges for society due to coronaviruses. Consequently, advancing models for the antiviral activity of therapeutic agents is a necessary component of the fast development of treatment for the virus. An analogy between anti-SARS agents suggested in 2017 and anti-coronavirus COVID-19 agents are quite probable. Quantitative structur
Document: The main protease (M(pro)) of SARS-associated coronavirus (SARS-CoV) had caused a high rate of mortality in 2003. Current events (2019–2020) substantiate important challenges for society due to coronaviruses. Consequently, advancing models for the antiviral activity of therapeutic agents is a necessary component of the fast development of treatment for the virus. An analogy between anti-SARS agents suggested in 2017 and anti-coronavirus COVID-19 agents are quite probable. Quantitative structure-activity relationships for SARS-CoV are developed and proposed in this study. The statistical quality of these models is quite good. Mechanistic interpretation of developed models is based on the statistical and probability quality of molecular alerts extracted from SMILES. The novel, designed structures of molecules able to possess anti-SARS activities are suggested. For the final assessment of the designed molecules inhibitory potential, developed from the obtained QSAR model, molecular docking studies were applied. Results obtained from molecular docking studies were in a good correlation with the results obtained from QSAR modeling.
Search related documents:
Co phrase search for related documents- accession number and acute respiratory syndrome: 1, 2, 3
- active site and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- active site enzyme and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
Co phrase search for related documents, hyperlinks ordered by date